Form 4: ClearPoint Neuro Director Acquires Shares
Statement of Changes in Beneficial Ownership
Director Pascal E. R. Girin acquired 755 shares of ClearPoint Neuro, Inc. common stock as compensation for board services.
Summary
- Director Pascal E. R. Girin received 755 shares of common stock on April 1, 2026.
- The shares were issued as payment for director fees under the company's Non-Employee Director Compensation Plan.
- The transaction was priced at $9.10 per share, based on the closing price on March 31, 2026.
- Following this transaction, the director's total beneficial ownership is 98,206 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.
Positives
- Director alignment with shareholders is reinforced through equity-based compensation.
- The transaction reflects standard corporate governance practices for non-employee director remuneration.
Negatives
- None identified.
Risks
- None identified.
Future Outlook
Not applicable.
Industry Context
StockSavvy.ai notes that equity-based compensation for board members is a standard industry practice to align director interests with long-term shareholder value in the medical device and neuro-technology sectors.
Comparison to Industry Standards
- The issuance of shares in lieu of cash fees is a common practice among small-cap medical technology companies to preserve cash reserves.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Issuance of equity in payment of fees under the Sixth Amended and Restated 2013 Incentive Compensation Plan. | 04/01/2026 | Standard alignment of director interests with company performance. |
Stakeholder Impact
- Minimal impact on shareholders as this is a routine compensation event.
Next Steps
- None.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Closing price date used for share issuance calculation. |
| 04/01/2026 | Date of the transaction. |
| 04/02/2026 | Date of filing. |
Keywords
ClearPoint Neuro, CLPT, Insider Trading, Director Compensation, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.